Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| HGH (Somatropin) | TB-500 (Thymosin Beta-4) | |
|---|---|---|
| Category | Growth Factors | Peptides |
| Standard Dose | Research indicates 1-2 IU daily for anti-aging and general optimization. 2-4 IU daily for body composition. 4-8+ IU daily in clinical GH deficiency (physician-supervised only). | Research indicates 2-2.5 mg administered twice weekly via subcutaneous injection. |
| Timing | Bedtime injection (mimics natural nocturnal GH surge) or morning fasted. Split dosing (AM + pre-bed) for higher doses. Always on empty stomach — carbohydrates blunt GH action. | No strict timing requirements. Can be administered at any time of day. Systemic action means injection location is not critical. |
| Cycle Duration | Continuous use is common in anti-aging protocols. 6-12 month minimum for full benefits. Clinical GHD treatment is typically lifelong. | Loading phase: 4-6 weeks. Total cycle: 8-16 weeks. |
| Evidence Level | strong_human | animal_plus_anecdotal |
Human Growth Hormone (somatropin) is a 191-amino acid single-chain polypeptide produced by anterior pituitary somatotrophs. It binds the GH receptor (GHR), activating JAK2-STAT5 signaling and MAP kinase pathways. Systemically, HGH upregulates hepatic IGF-1 production, which mediates most of its anabolic effects through IGF-1R/PI3K/Akt/mTOR-driven protein synthesis. Direct GH effects include lipolysis activation, insulin antagonism, chondrocyte/osteoblast stimulation, and enhanced collagen synthesis. Effects are divided into direct (lipolysis, insulin antagonism) and indirect (IGF-1-mediated growth and anabolism).
Research indicates 1-2 IU daily for anti-aging and general optimization. 2-4 IU daily for body composition. 4-8+ IU daily in clinical GH deficiency (physician-supervised only).
Bedtime injection (mimics natural nocturnal GH surge) or morning fasted. Split dosing (AM + pre-bed) for higher doses. Always on empty stomach — carbohydrates blunt GH action.
Continuous use is common in anti-aging protocols. 6-12 month minimum for full benefits. Clinical GHD treatment is typically lifelong.
TB-500 is a synthetic fragment of Thymosin Beta-4, a 43-amino acid protein that sequesters G-actin monomers, preventing premature polymerization and facilitating cellular migration and morphological changes essential for wound healing. It upregulates actin to promote cell migration, proliferation, and differentiation of stem/progenitor cells at injury sites. TB-500 also enhances angiogenesis, reduces inflammation, and promotes tissue remodeling through increased re-epithelialization and vascular density.
Research indicates 2-2.5 mg administered twice weekly via subcutaneous injection.
No strict timing requirements. Can be administered at any time of day. Systemic action means injection location is not critical.
Loading phase: 4-6 weeks. Total cycle: 8-16 weeks.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →